Advanced Proteome Therapeutics Corporation (APTCF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | - USD | 100.0% |
| 2022 | -957.36 Thousand USD | -42.19% |
| 2021 | -673.3 Thousand USD | -18.14% |
| 2020 | -569.93 Thousand USD | 38.46% |
| 2019 | -926.08 Thousand USD | 15.77% |
| 2018 | -1.09 Million USD | -2.08% |
| 2017 | -1.07 Million USD | -27.4% |
| 2016 | -845.49 Thousand USD | 36.36% |
| 2015 | -1.32 Million USD | -29.29% |
| 2014 | -1.02 Million USD | 5.28% |
| 2013 | -1.08 Million USD | -18.58% |
| 2012 | -914.77 Thousand USD | 15.42% |
| 2011 | -1.08 Million USD | 5.11% |
| 2010 | -1.13 Million USD | 3.77% |
| 2009 | -1.18 Million USD | 15.06% |
| 2008 | -1.39 Million USD | 35.55% |
| 2007 | -2.16 Million USD | -185432.85% |
| 2006 | -1166.00 USD | 99.68% |
| 2005 | -363.25 Thousand USD | -226.05% |
| 2004 | 288.17 Thousand USD | -10.82% |
| 2003 | 323.15 Thousand USD | -21.6% |
| 2002 | 412.19 Thousand USD | -7.11% |
| 2001 | 443.76 Thousand USD | 116.45% |
| 2000 | -2.69 Million USD | 3.38% |
| 1999 | -2.79 Million USD | -134.43% |
| 1998 | -1.19 Million USD | -149.74% |
| 1997 | 2.39 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | 100.0% |
| 2023 Q2 | -286.69 Thousand USD | -12.1% |
| 2023 Q1 | -255.75 Thousand USD | 0.54% |
| 2023 FY | - USD | 100.0% |
| 2023 Q3 | -149.77 Thousand USD | 47.76% |
| 2022 Q2 | -261.4 Thousand USD | -29.72% |
| 2022 FY | -957.36 Thousand USD | -42.19% |
| 2022 Q4 | -257.13 Thousand USD | -9.15% |
| 2022 Q1 | -201.5 Thousand USD | -17.73% |
| 2022 Q3 | -235.58 Thousand USD | 9.88% |
| 2021 FY | -673.3 Thousand USD | -18.14% |
| 2021 Q1 | -122.04 Thousand USD | 28.79% |
| 2021 Q2 | -187.65 Thousand USD | -53.76% |
| 2021 Q3 | -192.43 Thousand USD | -2.54% |
| 2021 Q4 | -171.16 Thousand USD | 11.05% |
| 2020 Q1 | -117.96 Thousand USD | 57.14% |
| 2020 Q3 | -137.62 Thousand USD | 3.69% |
| 2020 FY | -569.93 Thousand USD | 38.46% |
| 2020 Q4 | -171.39 Thousand USD | -24.53% |
| 2020 Q2 | -142.9 Thousand USD | -21.14% |
| 2019 Q2 | -206.44 Thousand USD | 24.13% |
| 2019 FY | -926.08 Thousand USD | 15.77% |
| 2019 Q1 | -272.08 Thousand USD | -41.5% |
| 2019 Q4 | -275.23 Thousand USD | -59.72% |
| 2019 Q3 | -172.32 Thousand USD | 16.53% |
| 2018 Q2 | -298.86 Thousand USD | -9.73% |
| 2018 Q1 | -272.35 Thousand USD | 13.14% |
| 2018 Q4 | -192.28 Thousand USD | 42.78% |
| 2018 FY | -1.09 Million USD | -2.08% |
| 2018 Q3 | -336.02 Thousand USD | -12.44% |
| 2017 FY | -1.07 Million USD | -27.4% |
| 2017 Q4 | -313.53 Thousand USD | -1.81% |
| 2017 Q3 | -307.94 Thousand USD | -19.13% |
| 2017 Q2 | -258.5 Thousand USD | -31.1% |
| 2017 Q1 | -197.18 Thousand USD | 28.99% |
| 2016 Q2 | -208.95 Thousand USD | -23.24% |
| 2016 Q3 | -189.31 Thousand USD | 9.4% |
| 2016 Q4 | -277.66 Thousand USD | -46.67% |
| 2016 Q1 | -169.55 Thousand USD | 44.05% |
| 2016 FY | -845.49 Thousand USD | 36.36% |
| 2015 Q3 | -257.56 Thousand USD | 12.17% |
| 2015 Q1 | -474.59 Thousand USD | -58.84% |
| 2015 FY | -1.32 Million USD | -29.29% |
| 2015 Q2 | -293.25 Thousand USD | 38.21% |
| 2015 Q4 | -303.06 Thousand USD | -17.67% |
| 2014 Q2 | -238.07 Thousand USD | -1.9% |
| 2014 Q4 | -298.78 Thousand USD | -16.25% |
| 2014 Q1 | -233.62 Thousand USD | 13.67% |
| 2014 Q3 | -257.02 Thousand USD | -7.96% |
| 2014 FY | -1.02 Million USD | 5.28% |
| 2013 Q1 | -222.54 Thousand USD | 28.38% |
| 2013 Q4 | -270.63 Thousand USD | 8.0% |
| 2013 Q3 | -294.15 Thousand USD | -1.4% |
| 2013 Q2 | -290.08 Thousand USD | -30.35% |
| 2013 FY | -1.08 Million USD | -18.58% |
| 2012 FY | -914.77 Thousand USD | 15.42% |
| 2012 Q1 | -165.69 Thousand USD | 30.08% |
| 2012 Q2 | -196.1 Thousand USD | -18.35% |
| 2012 Q3 | -241.68 Thousand USD | -23.24% |
| 2012 Q4 | -310.71 Thousand USD | -28.56% |
| 2011 Q4 | -236.98 Thousand USD | 21.23% |
| 2011 FY | -1.08 Million USD | 5.11% |
| 2011 Q3 | -300.85 Thousand USD | -9.99% |
| 2011 Q2 | -273.52 Thousand USD | -4.49% |
| 2011 Q1 | -261.77 Thousand USD | -46.23% |
| 2010 Q1 | -411.64 Thousand USD | -47.69% |
| 2010 Q3 | -262.65 Thousand USD | 8.41% |
| 2010 Q4 | -179.01 Thousand USD | 31.85% |
| 2010 FY | -1.13 Million USD | 3.77% |
| 2010 Q2 | -286.77 Thousand USD | 30.34% |
| 2009 Q2 | -284.54 Thousand USD | 16.34% |
| 2009 FY | -1.18 Million USD | 15.06% |
| 2009 Q3 | -280.85 Thousand USD | 1.3% |
| 2009 Q4 | -278.72 Thousand USD | 0.76% |
| 2009 Q1 | -340.12 Thousand USD | -0.08% |
| 2008 Q4 | -339.84 Thousand USD | 7.8% |
| 2008 Q1 | -356.86 Thousand USD | 75.43% |
| 2008 Q3 | -368.6 Thousand USD | -12.02% |
| 2008 Q2 | -329.05 Thousand USD | 7.79% |
| 2008 FY | -1.39 Million USD | 35.55% |
| 2007 Q2 | -173.95 Thousand USD | -133.73% |
| 2007 Q1 | -74.42 Thousand USD | -160.35% |
| 2007 FY | -2.16 Million USD | -185432.85% |
| 2007 Q4 | -1.45 Million USD | -199.88% |
| 2007 Q3 | -484.39 Thousand USD | -178.46% |
| 2006 Q4 | 123.33 Thousand USD | 336.55% |
| 2006 Q2 | -52.53 Thousand USD | -85.7% |
| 2006 Q1 | -28.28 Thousand USD | 92.49% |
| 2006 FY | -1166.00 USD | 99.68% |
| 2006 Q3 | -52.13 Thousand USD | 0.75% |
| 2005 Q4 | -376.54 Thousand USD | -1197.61% |
| 2005 FY | -363.25 Thousand USD | -226.05% |
| 2005 Q1 | 42.69 Thousand USD | -81.12% |
| 2005 Q2 | -63.71 Thousand USD | -249.21% |
| 2005 Q3 | 34.3 Thousand USD | 153.84% |
| 2004 Q3 | 49.07 Thousand USD | 170.57% |
| 2004 Q1 | 82.48 Thousand USD | -67.38% |
| 2004 Q4 | 226.16 Thousand USD | 360.89% |
| 2004 FY | 288.17 Thousand USD | -10.82% |
| 2004 Q2 | -69.53 Thousand USD | -184.31% |
| 2003 FY | 323.15 Thousand USD | -21.6% |
| 2003 Q3 | 84.8 Thousand USD | 141.72% |
| 2003 Q4 | 252.81 Thousand USD | 198.11% |
| 2003 Q1 | 188.79 Thousand USD | -41.79% |
| 2003 Q2 | -203.25 Thousand USD | -207.66% |
| 2002 Q3 | -67.29 Thousand USD | 91.13% |
| 2002 Q1 | -538.37 Thousand USD | -124.62% |
| 2002 FY | 412.19 Thousand USD | -7.11% |
| 2002 Q4 | 324.32 Thousand USD | 581.93% |
| 2002 Q2 | -758.33 Thousand USD | -40.86% |
| 2001 Q1 | -701.38 Thousand USD | 25.5% |
| 2001 FY | 443.76 Thousand USD | 116.45% |
| 2001 Q4 | 2.18 Million USD | 780.02% |
| 2001 Q3 | -321.59 Thousand USD | 53.74% |
| 2001 Q2 | -695.14 Thousand USD | 0.89% |
| 2000 Q3 | -270.08 Thousand USD | 69.94% |
| 2000 Q1 | -611.7 Thousand USD | 16.75% |
| 2000 FY | -2.69 Million USD | 3.38% |
| 2000 Q2 | -898.59 Thousand USD | -46.9% |
| 2000 Q4 | -941.46 Thousand USD | -248.58% |
| 1999 Q4 | -734.81 Thousand USD | -53.12% |
| 1999 Q3 | -479.87 Thousand USD | 48.21% |
| 1999 Q2 | -926.66 Thousand USD | -138.37% |
| 1999 Q1 | -388.75 Thousand USD | 70.78% |
| 1999 FY | -2.79 Million USD | -134.43% |
| 1998 Q1 | -497.05 Thousand USD | 0.0% |
| 1998 FY | -1.19 Million USD | -149.74% |
| 1998 Q3 | 698.51 Thousand USD | 1117.26% |
| 1998 Q2 | -68.66 Thousand USD | 86.19% |
| 1998 Q4 | -1.33 Million USD | -290.46% |
| 1997 FY | 2.39 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 100.0% |
| Nascent Biotech, Inc. | -2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | -664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.0% |
| Qrons Inc. | -643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | -13.67 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | -75.82 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 100.0% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.0% |
| Mesoblast Limited | -84.14 Million USD | 100.0% |
| Marizyme, Inc. | -34.08 Million USD | 100.0% |
| Genus plc | 6.4 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 100.0% |
| Pharming Group N.V. | -4.87 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 100.0% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 100.0% |
| ContraFect Corporation | -56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.0% |
| IMV Inc. | -38.67 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 100.0% |
| MultiCell Technologies, Inc. | -722.81 USD | 100.0% |
| ONE Bio Corp. | 13.68 Million USD | 100.0% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | -483.06 Thousand USD | 100.0% |
| Q BioMed Inc. | -3.44 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 100.0% |
| Biomind Labs Inc. | -1 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.0% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 100.0% |
| GB Sciences, Inc. | -1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.0% |
| HST Global, Inc. | -140.9 Thousand USD | 100.0% |
| CSL Limited | 3.7 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 100.0% |
| Halberd Corporation | -75.05 Thousand USD | 100.0% |
| Enzolytics Inc. | -2.14 Million USD | 100.0% |
| Agentix Corp. | -1.37 Million USD | 100.0% |
| Resverlogix Corp. | -12.74 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | -425.04 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 6.69 Million USD | 100.0% |
| Zenith Capital Corp. | -8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | -415.79 Million USD | 100.0% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 100.0% |
| Kadimastem Ltd | -3.04 Million USD | 100.0% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 100.0% |
| BioStem Technologies, Inc. | -7.77 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 100.0% |
| LadRx Corporation | -3.82 Million USD | 100.0% |
| Cell Source, Inc. | -4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 100.0% |
| NovAccess Global Inc. | -2.46 Million USD | 100.0% |
| Affymax, Inc. | -15.04 Million USD | 100.0% |
| Itoco Inc. | -919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.0% |
| Mobile Lads Corp. | -554.55 Thousand USD | 100.0% |
| CytoDyn Inc. | -18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 100.0% |
| SYBLEU INC | -149.18 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 100.0% |
| International Stem Cell Corporation | -663 Thousand USD | 100.0% |
| Bioxytran, Inc. | -3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | -36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | -735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 100.0% |
| Neutra Corp. | -229.48 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 100.0% |
| PureTech Health plc | -146.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 100.0% |
| IXICO plc | -1.43 Million USD | 100.0% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 100.0% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 100.0% |
| CSL Limited | 3.81 Billion USD | 100.0% |
| Cellectis S.A. | -108.85 Million USD | 100.0% |